Jul 30, 2020 / NTS GMT
Operator
Thank you for joining the earnings call for Sumitomo Dainippon Pharma. We will be presenting the financial results for the first quarter and development status update. Attendees from Sumitomo are Toru Kimura, Chief Scientific Officer; and Kashima-san from Finance and Accounting. Please refer to the slide deck on the corporate website. Please note that the conference call will be recorded and posted on the website.
Kashima-san will be giving the presentation first.
Hisayoshi Kashima - Sumitomo Dainippon Pharma Co., Ltd. - Senior Director & Corporate Controller
I would like to explain the first quarter financial results and development pipeline updates. Please look at Slide 3. This shows financial results for the first quarter. The numbers are shown on IFRS core basis. The revenues were JPY 133.9 billion, up by JPY 16.4 billion from the same period last year. The China segment declined, while Japan and North America segment increased revenues. SG&A expenses exceeded last year due to increased costs from Sumitovant consolidation, while sales promotion
Q1 2021 Sumitomo Dainippon Pharma Co Ltd Earnings Call Transcript
Jul 30, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers